Daniel O'Connell
Private Equity @ OrbiMed
New York, United States
Daniel O'Connell is a Series A investor at OrbiMed in New York focused on Biotechnology and Genetics. Daniel O'Connell, M.D., Ph.D., is an Associate on the Private Equity team. Before joining OrbiMed, Dr. O'Connell was the Associate Director of Cardiovascular Research at Arisaph Pharmaceuticals. In this role, he headed projects developing small molecules to raise HDL-cholesterol, culminating with an FDA filing of a novel compound in 2010.He has authored articles in peer-reviewed journals describing the design and synthesis of novel enzyme inhibitors and the effects of niacin in animal models of dyslipidemia. Dr. O'Connell received his MD and his PhD in biochemistry at Tufts University School of Medicine. He holds SB degrees from MIT in both chemistry and mathematics.
- Total investments:
- 3
- Last investment:
- Lead investor:
- 100%
Last updated:
For AI agents: llms.txt
Industries Daniel O'Connell invests in
Stages Daniel O'Connell invests in
Countries Daniel O'Connell invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 2 (67%)
- Genetics 1 (33%)
- Oncology 1 (33%)
- Health Care 1 (33%)
Stage
- Series A 2 (67%)
- Series B 1 (33%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Kivu Bioscience is a biotech company developing next-generation antibody-drug conjugates to deliver best-in-class therapeutics and focused on rapidly advancing next generation transformative assets. | $92M / Series A / Oct 28, 2024 | ||
| LogicBio develops gene therapy vectors for previously incurable genetic and infectious diseases, including: hemophilia, HIV/AIDS and methylmalonic acidemia (MMA). Our proprietary technology based on the non-pathogenic Adeno-Associated Viral (AAV) vector offers superior efficiency and safety compared to all competitors on the market, and isuniquely suited for the treatment of children as well as adults. | $45M / Series B / Jun 29, 2017 | ||
| LogicBio develops gene therapy vectors for previously incurable genetic and infectious diseases, including: hemophilia, HIV/AIDS and methylmalonic acidemia (MMA). Our proprietary technology based on the non-pathogenic Adeno-Associated Viral (AAV) vector offers superior efficiency and safety compared to all competitors on the market, and isuniquely suited for the treatment of children as well as adults. | $4M / Series A / Jan 20, 2016 |
Co-Investors
About OrbiMed
OrbiMed executes multiple investment strategies, including private equity for startups, public equity for traded entities, and private credit for commercial-stage companies. It offers structured debt and royalty monetization as non-dilutive financing solutions for owners of intellectual property and medical diagnostics. The firm manages a global portfolio that supports the development of new therapies, medical devices, and healthcare information technology systems.
OrbiMed Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Dina Chaya
Partner
|
|||
Kevin Koch
Venture Partner
|
|||
Rishi Gupta
Private Equity Partner
|
|||
Sunny Sharma
Senior Managing Director
|
|||
Tadd S. Wessel
Managing Director
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Daniel O'Connell invest in?
Daniel O'Connell invests primarily in Biotechnology, Genetics and Oncology startups, most often at Series A and Series B stage. Most of the 3 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Daniel O'Connell?
Public channels for Daniel O'Connell include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Daniel O'Connell last invest?
The most recent investment recorded for Daniel O'Connell closed in Oct 2024. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
